Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Invest Dermatol ; 143(6): 1023-1030.e7, 2023 06.
Artigo em Inglês | MEDLINE | ID: mdl-36581093

RESUMO

Stevens‒Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are severe cutaneous adverse drug reactions characterized by widespread keratinocyte cell death and epidermal detachment. At present, there is little understanding of how the detachment occurs or how it is abrogated by the TNF-α inhibitor etanercept, an effective SJS/TEN treatment. RNA sequencing was used to identify upregulated transcripts in formalin-fixed paraffin-embedded SJS/TEN skin biopsies. Epidermal matrix metalloproteinase 9 (MMP9) expression was assessed by immunohistochemistry in skin biopsies and cultured human skin explants exposed to serum from patients with cutaneous adverse drug reactions. TNF-α‒induced MMP9 expression and activity and its abrogation by etanercept were determined using the HaCaT immortalized keratinocyte cell line. Epidermal MMP9 expression was significantly higher in SJS/TEN skin (70.6%) than in healthy control skin (0%) (P = 0.0098) and nonbullous skin reactions (10.7%) (P = 0.0002). SJS/TEN serum induced significant MMP9 expression and collagenase activity in healthy skin explants, which was reduced by etanercept. Etanercept was also able to negate the TNF-α‒induced MMP9 expression in the HaCaT cell line. Data suggest that elevated epidermal MMP9 expression and collagenase activity are a putative pathogenic mechanism in SJS/TEN, which is limited by etanercept. Modulation of MMP9 expression and activity represents, to our knowledge, a previously unreported therapeutic target for the treatment of SJS/TEN.


Assuntos
Síndrome de Stevens-Johnson , Humanos , Síndrome de Stevens-Johnson/etiologia , Fator de Necrose Tumoral alfa/uso terapêutico , Metaloproteinase 9 da Matriz , Etanercepte/farmacologia , Etanercepte/uso terapêutico , Queratinócitos/patologia
2.
J Dermatolog Treat ; 33(5): 2687-2688, 2022 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-35238268

RESUMO

Clear cell acanthoma (CCA) is a rare, benign epidermal lesion of clear glycogen-containing keratinocytes. The exact etiology is unknown. Although CCA usually appear as solitary lesions, cases of multiple CCAs have also been described. The rare eruptive CCA variant describes cases with more than 30 lesions.Current therapeutic evidence for the management of multiple CCAs is limited. CO2 laser remains the most widely used laser in clinical practice. However, literature describing its effectiveness on CCA is sparse, and previous reports have described its use for a maximum of three lesions. To our knowledge, this is the first report of successful CO2 laser treatment of the multiple eruptive CCA variant with an excellent cosmetic outcome.Our case adds to the evidence that CO2 laser is an effective treatment for this condition. Particularly in those patients with refractory or multiple eruptive CCAs, or for those who may not tolerate repeated courses of cryotherapy, or who are concerned about scarring and cosmetic outcome.


Assuntos
Acantoma , Exantema , Terapia a Laser , Lasers de Gás , Neoplasias Cutâneas , Acantoma/patologia , Acantoma/cirurgia , Dióxido de Carbono , Humanos , Lasers de Gás/uso terapêutico , Neoplasias Cutâneas/patologia , Neoplasias Cutâneas/cirurgia
5.
Australas J Dermatol ; 57(3): e97-9, 2016 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-25872701

RESUMO

Cutaneous collagenous vasculopathy is a rare microangiopathy first described by Salama and Rosenthal in 2000. Several cases have been reported to date, describing distinct histological findings of thick hyaline collagenous blood vessel walls in the superficial dermis. Clinical confusion can arise with generalised essential telangiectasia. We report a case occurring in a 76-year-old woman who presented with a 2-year history of a telangiectatic rash progressing from her knees upwards. The diagnosis was confirmed on skin biopsy and treatment with pulsed dye laser was later initiated at the patient's request.


Assuntos
Vasos Sanguíneos/patologia , Colágeno/metabolismo , Dermatopatias Vasculares/patologia , Telangiectasia/patologia , Telangiectasia/radioterapia , Idoso , Biópsia por Agulha , Doença Crônica , Diagnóstico Diferencial , Progressão da Doença , Exantema/diagnóstico , Exantema/etiologia , Feminino , Humanos , Imuno-Histoquímica , Terapia com Luz de Baixa Intensidade/métodos , Doenças Raras , Dermatopatias Vasculares/diagnóstico , Telangiectasia/diagnóstico , Resultado do Tratamento , Reino Unido
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...